Immunogenicity and safety of an MF59-adjuvanted cell-derived higher-dose quadrivalent influenza vaccine (aQIVc) in adults aged 50 years or older: a phase 3 randomised controlled trial

Study limitation reported by the research below: “Study enrolled only 'healthy' adults, so findings may not extend to immunocompromised individuals or those with significant comorbidities.”